IP Library Granted Patent US 8,501,740
Granted Patent B2
US 8,501,740 · App. 12/682,064 · Granted Aug 6, 2013

Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors

Inventor: Howard Gutstein (Bellaire, TX)
Assignee: Board of Regents, The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,740
App. No.
12/682,064
Granted
Aug 6, 2013
Kind
B2
Abstract

Methods of preventing the development and reversing or partially reversing opioid tolerance in a subject are provided herein. Such methods include the step of administering to a subject in need thereof a therapeutically effective amount of a PDGFR modulator or EGFR modulator alone or together with an opiate analgesic. The methods can also be used for the treatment of refractory neuropathic pain, physical dependence or addiction.

Claims (5)

1. A method of treating morphine tolerance comprising the step of administering to a subject in need thereof a therapeutically effective amount of imatinib administered to the subject in an aqueous pharmaceutical formulation comprising cyclodextrin, cyclodextran, or other cycloamyloses.

2. A method of claim 1 wherein imatinib is administered to the subject in combination with at opioid selected from morphine, fentanyl, codeine, thebaine, diacetylmorphine (heroin), dihydrocodeine, hydrocodone, hydromorphone, nicomorphine, oxycodone, oxymorphone, alphamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanyl, and ohmefentanyl.

3. The method of claim 1 , wherein the drug is administered spinally, intravenously, intraperitoneally, intramuscularly, subcutaneously, or orally.

4. The method of claim 1 , wherein the aqueous formulation comprises a cyclodextrin, and the cyclodextrin is cyclodextrin sulfobutyl ether.

5. The method of claim 4 , wherein the cyclodextrin sulfobutyl ether is sulfobutylether-7-b-cyclodextrin.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 24, 2018
From: UNIVERSITY OF TX MD ANDERSON CAN CTR
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045164/0052 →
CONFIRMATORY LICENSE Recorded Jan 19, 2018
From: MD ANDERSON CANCER CENTER
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 044666/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2010
From: GUTSTEIN, HOWARD B.
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 024214/0697 →
Continuity (2)
Provisional Application 60978641 · Oct 9, 2007
Related Publication 20100210709A1 · Aug 19, 2010